Oncotelic Therapeutics Inc Stock Price, News & Analysis

Oncotelic Therapeutics (OTLC) has officially launched an animal health division, emphasizing its commitment to innovative drug development for animals, particularly pets. The initiative aims to utilize blockchain technology and a decentralized autonomous organization (DAO) to improve drug development processes. Chairman and CEO Dr. Vuong Trieu expressed optimism about the integration of DAOs within the animal health sector and the potential for existing drug candidates to succeed in this new market. The company acknowledges the inherent risks in its forward-looking statements related to future product development and regulatory approvals.

Oncotelic Therapeutics (OTCQB:OTLC) announced its presentation at the SITC 37th Annual Meeting, scheduled for November 10-12, 2022, in Boston, MA. The presentation, titled Mechanism of Action for OT-101 TGF-ß immunotherapy, focuses on the ongoing development of OT-101 for pancreatic cancer treatment. CEO Dr. Vuong Trieu highlighted that pancreatic cancer has a low survival rate, urging the need for innovative therapies. The P001 trial showed 54% disease control in evaluable patients, indicating promising results for OT-101 against this aggressive cancer.

Oncotelic Therapeutics (OTCQB:OTLC) has announced two poster presentations at the 2022 Society for Neuro-Oncology Annual Meeting scheduled for November 16-20, 2022, in Tampa Bay, Florida. The presentations will focus on OT-101, a treatment for glioblastoma and DIPG, emphasizing its potential after radiation therapy. Dr. Vuong Trieu, CEO, highlighted the urgent need for innovative treatments for DIPG, a fatal pediatric brain cancer. Oncotelic aims to accelerate OT-101's clinical development following the formation of a joint venture with Sapu Bioscience.

Oncotelic Therapeutics (OTLC) reported a net profit of $17 million for Q2 2022, driven by a fair value of $22.6 million for its joint venture (JV) with Dragon Overseas and GMP Biotechnology. Noteworthy highlights include a significant reduction in expenses by over $3.5 million compared to Q2 2021 and a strategic plan for OT-101's further development, targeting pediatric cancers. The JV is positioned for an IPO, and Oncotelic anticipates lower R&D and G&A expenses moving forward.

Oncotelic Therapeutics (OTCQB:OTLC) announced participation in Biotechgate Digital Partnering from Aug 29 - Sep 2, 2022. The company focuses on developing treatments for rare conditions like Parkinson's disease and certain cancers, particularly pediatric cancers. Oncotelic has joint ventures and its own product candidates, including AL-101 for Parkinson's and erectile dysfunction. As of now, over 1 million patients in the US have Parkinson's, with numbers projected to rise. The company has completed several clinical trials for its therapies, including OT-101 for cancer and COVID-19.

Oncotelic Therapeutics (OTCQB:OTLC) announced the availability of its presentation at the 7th JCA-AACR Special Joint Conference, focusing on its clinical findings for OT-101 treatment in pancreatic cancer. Key results indicate that over 55% of treated patients achieved long-term disease control, significantly improving median overall survival to 9.3 months compared to 2.6 months (p<0.0001). Additionally, high AUC levels during subsequent chemotherapy correlated with a median overall survival of 9.6 months (p=0.0006). The presentation can be accessed through their website and YouTube.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced its presentation at the BIO International Convention is now available. The company is on track for a Joint Venture Company initial public offering in 2023, with a minimum valuation of $200M and a potential range of $1B to $5B. They are combining their drug OT-101 with established immunotherapies, with promising results reported in COVID-19 mortality rates. OT-10 has shown a significant reduction in mortality among high-risk COVID patients, with a statistical significance of p=0.003.

Oncotelic Therapeutics (OTCQB:OTLC) announced the FDA clearance for its Phase 2 clinical trial protocol targeting metastatic pleural mesothelioma (MPM). This trial, in collaboration with Merck, utilizes pembrolizumab and aims to investigate the combination of TGF-β inhibition (OT-101) with anti-PD-1 therapy. The study will enroll up to 63 patients and assess tumor response, safety, and tolerability, with primary objectives focusing on improving overall response rates in MPM patients who haven't responded to existing treatments.

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) reported Q1 2022 financial results, showing a net loss of $5 million, compared to a loss of $3.1 million in Q1 2021. R&D expenses decreased to $580K from $1.6 million due to reduced clinical trial activity. G&A expenses increased by $3.3 million, largely due to non-cash stock compensation. The company established a joint venture with Dragon Overseas and GMP Bio, which could yield up to $50 million upon OT-101's marketing approval. Oncotelic aims to uplift to a national exchange, supported by this JV which transfers clinical trial costs away from the company.